Evidence map›Paper›PMID 26571119›Full record

ArticlePloS one2015

All-Trans Retinoic Acid-Induced Deficiency of the Wnt/β-Catenin Pathway Enhances Hepatic Carcinoma Stem Cell Differentiation.

Xinfeng Zhu, Wenxue Wang, Xia Zhang, Jianhua Bai, Gang Chen, Li Li, Meizhang Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. WNT Signaling in Cardiac and Vascular Disease.Pharmacological reviews · 2018
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xinfeng ZhuAffiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan Province, 650011, P. R. China.
Wenxue WangLaboratory of Biochemistry and Molecular Biology, School of Life Sciences, Yunnan University, Kunming, Yunnan Province, 650091, P. R. China.
Xia ZhangAffiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan Province, 650011, P. R. China.
Jianhua BaiAffiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan Province, 650011, P. R. China.
Gang ChenAffiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan Province, 650011, P. R. China.
Li LiAffiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan Province, 650011, P. R. China.
Meizhang LiLaboratory of Biochemistry and Molecular Biology, School of Life Sciences, Yunnan University, Kunming, Yunnan Province, 650091, P. R. China.
Kunming Medical University · CNYunnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoic acid (RA) is an important biological signal that directly differentiates cells during embryonic development and tumorigenesis. However, the molecular mechanism of RA-mediated differentiation in hepatic cancer stem cells (hCSCs) is not well understood. In this study, we found that mRNA expressions of RA-biosynthesis-related dehydrogenases were highly expressed in hepatocellular carcinoma. All-trans retinoic acid (ATRA) differentiated hCSCs through inhibiting the function of β-catenin in vitro. ATRA also inhibited the function of PI3K-AKT and enhanced GSK-3β-dependent degradation of phosphorylated β-catenin. Furthermore, ATRA and β-catenin silencing both increased hCSC sensitivity to docetaxel treatment. Our results suggest that targeting β-catenin will provide extra benefits for ATRA-mediated treatment of hepatic cancer patients.

Indexed as

AC133 AntigenAntigens, CDApoptosisbeta CateninCell DifferentiationCell Line, TumorDocetaxelGlycoproteinsHep G2 CellsHumansImmunohistochemistryLiver NeoplasmsNeoplastic Stem CellsOxidoreductasesPeptidesReal-Time Polymerase Chain ReactionAC133 AntigenAntigens, CDbeta CateninDocetaxelGlycoproteinsOxidoreductasesPeptidesRNA, Small InterferingTaxoidsTretinoin

Identifiers

PMID26571119
PMCPMC4646487
OpenAlexW2179783379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.